

7th August, 2023

BSE Limited
P.J. Towers, Dalal Street, Fort,
Mumbai- 400 001
BSE scrip code: 543635

National Stock Exchange of India Limited
Exchange Plaza, Bandra-Kurla Complex,
Bandra (East), Mumbai – 400 051
NSE symbol: PPLPHARMA

Sub: SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015
(‘Listing Regulations’) - Transcript of Conference Call with Investors/Analysts

Dear Sir / Madam,

In continuation to our letter dated 28th July, 2023 and pursuant to Regulation 30 read with Para A Part A of Schedule III of the Listing Regulations, please find enclosed the transcript of the Conference Call held on 4th August, 2023 on discussion of the Q1 FY2024 Results of the Company.

The transcript of the said conference call is also hosted on the website of the Company at <https://www.piramal.com/investor/piramal-pharma-limited/financial-reports/investor-calls/>

Kindly take the above on record.

Thanking you,

Yours truly,

For **Piramal Pharma Limited**

Tanya Sanish
Company Secretary

Piramal Pharma Limited

CIN: U24297MH2020PLC338592

Registered Office: Gr. Flr. Piramal Ananta, Agastya Corporate Park, Opp Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai – 400070 India

T +91 22 3802 3000 / 4000

[piramal.com](https://www.piramal.com)